Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orthovita's Cellpaker plasma collector

This article was originally published in Clinica

Executive Summary

The US FDA has sanctioned Orthovita's premarket approval (PMA) supplement to sell Cellpaker plasma collection systems that are manufactured at its subcontractor's facility. The system is used with the firm's surgical haemostat Vitagel. Cellpaker collects the patient's own plasma, which is then mixed with the haemostat before use in surgery. Malvern, Pennsylvania-based Orthovita has been distributing Vitagel and Cellpaker since January 2005 under a deal with Angiotech BioMaterials. Pursuant to a March 2006 licence pact with its partner's affiliate, Angiotech Pharmaceuticals, manufacturing obligations for both products shifted to Orthovita. Orthovita started manufacturing Vitagel in July 2006 and said it would immediately start sales of Cellpaker manufactured on its behalf.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT047540

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel